The US Department of Health and Human Services has reinstated the vaccine safety task force nearly three decades after its dissolution, aiming to improve oversight and vaccine safety amidst public scrutiny. Meanwhile, the biopharma sector reports fewer IPOs but substantially larger deal sizes, with deal values exceeding prior years amid cautious market dynamics. Additionally, pricing strategies and regulatory decisions continue to shape industry trajectories as companies seek to reconcile innovation costs with market demands.